Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with the report dated April 26, 2022. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of an insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $44.8700 |
| Volume | 1,147.942 ADSs |
| Transaction Date | April 22, 2022 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction executed within Dr. Barron's GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a standard compliance notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: The purchase was made through an Executive Supplemental Savings Plan, not necessarily a direct open-market purchase.
- Volume and Price: Approximately 1,148 ADSs were acquired at $44.87 per share.
- Financial Data Absence: Investors should note that this filing does not contain quarterly or annual financial results.